BRISBANE, Calif.--(BUSINESS WIRE)--Nov. 28, 2018--
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company
developing treatments for potentially life-threatening food allergies,
today announced the closing of the $98 million equity investment by
Nestlé Health Science. Nestlé Health Science purchased 3,237,529 newly
issued shares of Aimmune’s common stock at $30.27 per share on November
28, 2018, in a private placement transaction. The sale of shares was
made pursuant to the terms of the Securities Purchase Agreement entered
into on November 11, 2018, by Aimmune and Nestlé Health Science, as
previously reported by Aimmune.
Additional details regarding the equity investment and strategic
collaboration agreement can be found in Aimmune’s Form 8-K filed with
the Securities and Exchange Commission on November 13, 2018.
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a biopharmaceutical company developing
treatments for life-threatening food allergies. The company’s
Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is
intended to provide meaningful levels of protection against allergic
reactions resulting from accidental exposure to food allergens by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational biologic product using CODIT™, AR101 for
the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4–17 years of age. Aimmune plans to submit regulatory filings for
marketing approval of AR101 in the United States and Europe based on
data from the pivotal Phase 3 PALISADE clinical trial of AR101, which in
4–17-year-old subjects met its primary and key secondary endpoints, and
additional ongoing and completed AR101 clinical trials. For more
information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181128005724/en/
Source: Aimmune Therapeutics, Inc.
Laura Hansen, Ph.D.